Neurophysiological methods have been used in the investigation of myasthenic patients for two main reasons. The diagnostic value of different methods have been demonstrated since the early reports of changes in muscle response to repetitive nerve stimulation. Over the decades these methods have also been used to help understand the pathophysiological mechanisms of myasthenia gravis (MG) and, in spite of the recent recognition of the immunological defect in MG, neurophysiological methods still have to be used to demonstrate the functional effects of the morphological or molecular changes demonstrated with other techniques. This paper will deal with some clinical neurophysiological methods for the diagnosis of disturbed neuromuscular transmission, both those commonly used and others at present used only in certain laboratories.
MG has attracted considerable attention out of proportion to the actual number of patients with the disease. This is mainly due to the early report of positive therapeutic effects of cholinesterase inhibitors, thymectomy, lymph drainage, corticosteroids, 4-aminopyridine, and other drugs as well as exciting new knowledge about the pathogenesis, including the development of a useful animal model. The disease may also provide a model for the further understanding of other immunologically induced diseases.
Efficient diagnostic methods are of great importance in order to recognise myasthenic patients among those with muscle fatiguability and to follow the effect of different therapeutic measures. Over the years Ian Simpson has contributed much to the knowledge of MG and has inspired enthusiasm among those working with these problems. As a clinical scientist he acknowledged and used neurophysiological methods in the battery of tests of neuromusclar transmission. He was the first to draw attention to the correlation of MG with autoimmune disorders. As The similarity between the decremental response in MG and that of the curarised normal muscle, the worsening in MG after intra-arterial injection of acetylcholine (ACh), and the abnormal response to other depolarising agents was taken as evidence that MG was due to a postsynaptic defect. Desmedt et al7-9 using the same techniques found greater similarity between MG and the effects of hemicholinium which inhibits the uptake of choline producing a presynaptic block due to reduced ACh synthesis, and therefore considered MG to be a presynaptic disorder.
Since the decrement method does not allow localisation of the defect in greater detail a more direct method was necessary. This came when the technique of intracellular recordings from human intercostal muscles was introduced for the study of myasthenic motor end-plates.10 11 Intracellular recordings are used in some laboratories for diagnosis of MG but the method is 623 complicated and has its main use in research. It 
Clinical electrophysiology in myasthenia gravis
After a period of maximal activation or high frequency repetitive stimulation (the latter is not used in our department since it is uncomfortable for the patient although it is considered to be a better controlled activation) the amplitude and area are mainly unchanged in the normal muscle. In the myasthenic muscle (not overtreated with cholinesterase inhibitors) the decrement becomes less pronounced or disappears and an eventually reduced resting amplitude is increased towards normal values, an effect seen only during the first 20-30 seconds after the activation. This is again the normal phenomenon of facilitation of ACh release in the motor end-plates. It is unmasked in situations where the increase in ACh may contribute positively to restoration of transmission. In conditions where disturbed neuromuscular transmission is mainly caused by impaired release, typically in Eaton-Lambert syndrome, the effect of this facilitation is particularly pronounced. On the other hand in conditions where an overexposure to ACh is causing the dysfunction (such as overtreatment with cholinesterase inhibitors,17 intoxication with organophosphorus compounds, '8) there is no increase of the recorded response but rather a reduced amplitude directly after maximal voluntary contraction or tetanic stimulation. The amplitude of the response at the height of the facilitation gives an indication of the total number o f motor end-plates that can be activated, that is, not irreversibly blocked or destroyed and the measure is thus of practical value.
After this short period of facilitation in the myasthenic muscle the amplitude decreases and the decrement becomes more pronounced. This is called the postactivation exhaustion and was first described by Desmedt.19 This parameter seems physiologically closer to the fairly reversible myasthenic fatique after exercise than the decrement. The cause of the postactivation exhaustion is not yet clear. The receptors are known to show "desensitisation" experimentally after even a short exposure to ACh20 and this may play a role but further investigations are necessary.
In all tests it should be remembered that facilitation and exhaustion are two separate phenomena acting at the same time but with different time scales, and that the obseived response is determined by the summated effect of the two. 
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Cliniic al electrophy7s,iology inmyasthenia gravIis Based on the increased sensitivity of patients with MG to curare, this drug has been used to reveal a neuromuscular distuitbance. In order to reduce the risk the test is made after regional intravenous administration.31 A diagnostic yield of Ip to 960 in generalised MG is reported. 12 A curare test is considered potentially hazardous and its use has therefore been discouraged in most laboratories.
Staircase phenlomnenonl Decrement of the electrical response as described above is usually the commonly used test of the MG defect but it can be measured from the mechanical response as well. In this situation not only is neuromuscular transmission tested but also the contractile characteristics of the muscle fibres. With low frequency stimulation (2 Hz) normal muscle shows a slow increase in twitch amplitude during the first minutes of stimulation. This is assumed to be an effect of intensified excitation-contraction process. In myasthenia this so called staircase phenomenon was reported to be abnormally wveak or by some authlors absent33 whereas others9 reported that the staircase phenomenon was usually within normal limits. If it i.s abnormal, after the amplitude reduction in the electrical response caused by neuromuscular transmission is considered, it should suggest defects in MG other than those located at the motor end-plate. The jitter value is different for motor end-plates even within the same motor unit. Different muscles have a different mean jitter value within the same subject and the mean value for one particular muscle differs between subjects. After a small standard dose of curare the jitter value increases less in those motor end-plates with an initially low value than in those with an initially high jitter value. It seems that the jitter value in a motor end-plate is an indicator of its safety factor expressed as sensitivity to curare, that is, low jitter suggests less sensitivity. In myasthenia gravis the jitter is typically increased. The degree of abnormality in one muscle shows a range from normal motor end-plates to those with pronounced changes including partial or total blocking (fig 3) . This range of abnormality is also seen within the same motor unit ( fig 3C) . When using the SFEMG method it is therefore necessary to make recordings from at least 20 different electrode positions. The In Eaton-Lambert syndrome the jitter is increased. It has the same characteristics as jitter in MG except for the reaction to increased firing rate. In MG the jitter and degree of blocking increases, in Eaton-Lambert syndrome they decrease when the innervation rate is increased.
In some clinically diagnosed patients with MG a proportion of the abnormal motor end-plates show, in contrast to the larger part of the motor endplates, a slight improvement during continuous voluntary activation as described for the EatonLambert syndrome. Thus patients with clinical myasthenia may have a mixture of motor end-plate defects, some typical for MG, some similar to those found in the myasthenic syndrome. This intermediate form is sometimes seen also with decrement testing in these patients. 37 SFEMG has been performed in 164 In the patients where the treatment had been used for more than one month the FD was increased from the normal mean by 2-2 SD (p<0-01) in the biceps brachi muscle compared to 1-2 SD in the untreated patients. The difference was most pronounced in older treated patients. In the cases where biopsy had been taken the degree of fibre type grouping was correlated to the FD. The increased fibre density most likely reflects denervation caused by the cholinesterase inhibitors. Signs of denervation can also be induced in animals.41 42 The slight increase in average fibre density in the nontreated group as compared to a normal value is statistically significant (p < 0-01). This may be due to the morphological changes of the myasthenic motor endplate43 44 In this paper the value of measuring the antibody titre against acetylcholine receptor has not been discussed. This test demonstrates the immunological abnormality and has obvious advantages. So far the test is not correlated to the clinical severity of the disease and has unfortunately, like the other tests, the lowest yield in ocular myasthenia.
The discrepencies in the results when using the different electrophysiological and immunological tests may indicate that myasthenia gravis is a heterogenous entity within which subgroups may be identified. It is a challenge for further studies of myasthenia gravis and the myasthenic syndromes. The project is supported by the Swedish Research Council (Grant 135). The collaboration of Dr P 0 Osterman who examined most of the patients in the SFEMG study and Dr Ann Kari Lefvert who measured the receptor antibodies is acknowledged.
